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Abstract
Background: The gut microbiota is thought to play a key role in the development of the inflammatory bowel
diseases Crohn’s disease (CD) and ulcerative colitis (UC). Shifts in the composition of resident bacteria have been
postulated to drive the chronic inflammation seen in both diseases (the “dysbiosis” hypothesis). We therefore
specifically sought to compare the mucosa-associated microbiota from both inflamed and non-inflamed sites of
the colon in CD and UC patients to that from non-IBD controls and to detect disease-specific profiles.
Results: Paired mucosal biopsies of inflamed and non-inflamed intestinal tissue from 6 CD (n = 12) and 6 UC (n =
12) patients were compared to biopsies from 5 healthy controls (n = 5) by in-depth sequencing of over 10,000
near full-length bacterial 16S rRNA genes. The results indicate that mucosal microbial diversity is reduced in IBD,
particularly in CD, and that the species composition is disturbed. Firmicutes were reduced in IBD samples and there
were concurrent increases in Bacteroidetes, and in CD only, Enterobacteriaceae. There were also significant
differences in microbial community structure between inflamed and non-inflamed mucosal sites. However, these
differences varied greatly between individuals, meaning there was no obvious bacterial signature that was
positively associated with the inflamed gut.
Conclusions: These results may support the hypothesis that the overall dysbiosis observed in inflammatory bowel
disease patients relative to non-IBD controls might to some extent be a result of the disturbed gut environment
rather than the direct cause of disease. Nonetheless, the observed shifts in microbiota composition may be
important factors in disease maintenance and severity.
Background
Inflammatory bowel disease (IBD) encompasses both
Crohn’s disease (CD) and ulcerative colitis (UC), chronic
inflammatory disorders of the gastrointestinal tract with
developed world predominance and an incidence that
has risen dramatically in the post-war period [1]. IBD
m a n i f e s t sw i t hs y m p t o m ss u c ha ss e v e r ed i a r r h o e a ,
weight loss and debilitating abdominal pain, resulting in
substantial morbidity and impairment in quality of life
[2]. In both diseases visibly inflamed and non-inflamed
areas of intestine can be identified at assessment by
colonoscopy.
The cause of both conditions is still speculative. Host
genetics play a key role, with genetic factors more
important for development of CD than UC [3,4], but
genetic defects cannot wholly explain the increasing
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any medium, provided the original work is properly cited.prevalence of IBD in recent years, suggesting that envir-
onmental factors are also involved [5]. The current gen-
erally accepted disease hypothesis is that the chronic
inflammation of IBD results from a genetically dysregu-
lated host immune response directed at the gut micro-
biota [6-8].
The human gut microbiota is a highly diverse and
abundant community of microbes that under normal
circumstances is either commensal or beneficial to
human health [9]. Bacteria in the gut contribute to host
nutrition via production of short chain fatty acids and
vitamins, and play integral roles in maintaining human
health by preventing colonisation by pathogens and by
shaping and maintaining normal mucosal immunity
[10]. The microbiota is also, however, a major source of
antigens, including lipopolysaccharides, peptidoglycan,
lipoproteins, flagellin and unmethylated CpG-containing
DNA, all of which can activate both innate and adaptive
immune responses [11,12]. A balanced relationship,
therefore, must exist between bacteria and their human
hosts. A disruption in this homeostasis threatens the
state of immune tolerance and may result in gut
inflammation.
Several lines of evidence suggest a role for gut bacteria
in the pathogenesis of IBD. Faecal stream diversion
induces remission in CD [13], animal models of colitis
require the presence of gut bacteria to initiate inflamma-
tion (reviewed in [14]), an increased mucosal bacterial
load is observed in IBD patients [15,16], genome-wide
IBD association studies have identified polymorphisms
in genes involved in bacterial recognition and clearing
(reviewed in [17]) and broad-spectrum antibiotics have
some efficacy in the treatment of CD [18,19].
With CD in particular, individual species such as
Mycobacterium avium subspecies paratuberculosis or
Escherichia coli have been implicated in disease aetiol-
ogy [20,21] while the emerging “dysbiosis” hypothesis
implicates multi-species assemblages in an overall imbal-
ance between harmful and protective bacteria [22,23].
Numerous studies have attempted to characterise the
microbial communities in IBD and to compare these
with healthy individuals. Results indicate that individuals
with IBD have reduced bacterial diversity, temporal sta-
bility and cluster separately when compared to healthy
controls [24-28]. Compositional comparisons have gen-
erated inconsistent results but have generally identified
reductions in components of the Firmicutes phylum in
IBD, often, but not always, with concurrent increases in
Bacteroidetes and facultative anaerobes such as Entero-
bacteriaceae [12,22,29-31].
Faecal/luminal bacterial communities have repeatedly
been shown to be distinct from mucosal communities
[32-37], meaning that study of the IBD mucosa-
associated microbiota and comparison with those from
healthy individuals should provide the best insight into
whether or not a particular microbial signature is dis-
ease specific. In addition, within IBD-affected intestines
disease-causing agents might be enriched at sites of
active inflammation relative to comparatively unaffected
mucosa. We have therefore used in-depth bacterial 16S
rRNA gene cloning and sequencing technology to com-
pare the mucosa-associated microbiota from inflamed
and non-inflamed sites of the colon in CD and UC
patients and in non-IBD controls. Our findings indicate
that mucosal microbial diversity and composition is dis-
turbed in IBD and that there are significant differences
in microbial community structure between inflamed and
non-inflamed mucosa.
Results
Twenty-nine mucosal biopsies were collected from a
total of seventeen patients, including paired biopsies of
inflamed and non-inflamed tissue from six patients with
active CD (n = 12), paired biopsies from six patients
with active UC (n = 12) and five biopsies from non-IBD
controls (n = 5). Demographic data, disease phenotype,
biopsy site and histological scores are shown in Table 1.
All biopsies from non-IBD controls were histologically
normal. There was no age difference between CD and
UC cases but, due to the indication for colonoscopy, the
average age of the non-IBD control patients was higher.
The median ages were 32 (25-51) years for the CD
group, 26 (24-73) years for the UC group and 51 (45-73)
years for the controls. Disease duration was similar.
Quantification of bacterial populations
Using qPCR we measured the total bacterial load in the
mucosal biopsy samples. The results showed high varia-
bility between samples but overall the biopsies from the
inflamed intestinal regions of CD patients contained the
lowest number of bacteria (Figure 1). The total number
of bacteria detected in these inflamed CD samples was
significantly lower than the bacterial load present in the
inflamed regions of the UC patients’ colons. While it
appeared that within each disease cohort the bacterial
load was generally lower in inflamed regions of the
c o l o nc o m p a r e dt on o n - i n f l a m e dr e g i o n st h ei n t e r -
individual variation meant that no other significant
differences were detected.
Overall phylogenetic classification of 16S rRNA gene
sequences
We next analysed the bacterial diversity in the 29 muco-
sal biopsy samples by deep sequencing of 16S rRNA
gene clone libraries. The final dataset of 10,010 chi-
mera-checked, full-length sequences included an average
of 620 clones per CD patient, 750 clones per UC patient
and ~350 clones per healthy control. As a whole, the
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at >99% sequence identity), which could be mapped to
eight bacterial phyla. 93% of the sequences belonged to
just two of these phyla; the Firmicutes (51.8% of clones)
and the Bacteroidetes (41.1%). Within the Firmicutes
phylum the vast majority of sequences grouped into two
families, the Lachnospiraceae (51.2%) and the Rumino-
coccaceae (33.1%), which comprise clostridial clusters
XIVa and IV respectively. The Bacteroidetes sequences
were predominantly from the Bacteroidaceae family
(62.6%) but also included Porphyromonadaceae,m a i n l y
Parabacteroides species, (13%) and Prevotellaceae (19%).
Proteobacteria represented ~6% of the total sequences,
t h em a j o r i t yo fw h i c hw e r eb-proteobacterial species
related to Sutterella spp. The remaining five phyla we
detected each accounted for less than 1% of total bac-
teria: Actinobacteria (0.89%), Fusobacteria (0.14%), Ver-
rucomicrobia (0.03%), Lentisphaera (0.01%) and TM7
bacteria (0.02%).
Comparison of bacterial composition in IBD and control
biopsies
There was a large degree of inter-individual variation
between patients at all taxonomic levels but, despite
this, distributions could be significantly associated with
disease. Samples from both the inflamed and non-
inflamed sites from CD and UC patients contained pro-
portionally less Firmicutes, and correspondingly more
Bacteroidetes, than the non-IBD control samples
(Figure 2). The decreased proportion of Firmicutes pre-
sent in UC, but not CD, samples reached statistical sig-
nificance when compared with the controls (Figure 2).
Related to these shifts, the ratio between Firmicutes and
Bacteroidetes was changed in IBD patients. In non-IBD
controls there were significantly more Firmicutes than
Bacteroidetes, but this difference was lost with disease
(Figure 2). We also observed a slight increase in Entero-
bacteriaceae in CD samples. Enterobacteriaceae were
detected in 2 out of the 5 control patients and
accounted for 0.11% of the total pooled community
from these samples; they were detected in samples from
2 out of 6 UC patients and accounted for 0.09% of the
total pooled community from these samples. In contrast,
Enterobacteriaceae were detected in the paired biopsy
samples from 5 out of the 6 CD patients included in the
study and accounted for a ten-fold increase in propor-
tion of the total CD microbiota compared to the other
Table 1 Characteristics of patients and biopsy tissue at time of sampling
Diagnosis No. Age Sex Biopsy Site Baron Score Biopsy site Baron Score
CD 1 51 M Rectum 3 Descending 0
CD 2 25 F Descending 2 Descending 0
CD 3 35 F Sigmoid 3 Descending 1
CD 4 29 F Transverse 2 Sigmoid 0
CD 5 35 F Sigmoid 2 Transverse 0
CD 6 26 M Transverse 3 Sigmoid 0
UC 1 49 M Sigmoid 1 Transverse 0
UC 2 26 M Sigmoid 2 Sigmoid 0
UC 3 73 M Rectum 1 Descending 0
UC 4 25 M Transverse 2 Ascending 0
UC 5 26 M Sigmoid 2 Splenic 0
UC 6 24 F Rectum 2 Descending 0
Non-IBD 1 72 F n/a n/a Sigmoid n/a
Non-IBD 2 51 F n/a n/a Rectum n/a
Non-IBD 3 48 F n/a n/a Rectum n/a
Non-IBD 4 45 M n/a n/a Terminal Ileum n/a
Non-IBD 5 73 M n/a n/a Descending n/a
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Figure 1 qPCR analysis of total bacterial load in mucosal
biopsy samples. Figures are mean results for each patient cohort.
Error bars denote standard deviation from the mean. Total bacterial
load was significantly lower in the inflamed CD biopsies than the
UC inflamed biopsies.
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compared to UC samples (p = 0.049) but did not reach
significance when compared to the non-IBD control
cohort (p = 0.069). We could find no significant associa-
tion, however, between microbiota composition and the
severity of inflammation or the site of mucosal biopsy.
Measurements of bacterial diversity
Using a number of different measures to explore the
bacterial diversity within our samples we found that
there was reduced diversity in biopsies from IBD
patients compared to controls and that the reduction
was particularly apparent in patients with CD (Figure 3).
Rarefaction curves built from the cumulative dataset
revealed that there were significant differences in species
richness between control and CD samples (Figure 3A).
The rarefaction curves also revealed a trend towards a
slight increase in species richness in inflamed versus
non-inflamed tissues, although these difference were not
significant. In agreement with these findings, using the
Shannon diversity index (SDI) to measure the richness
and evenness of each sample, we found that the indivi-
dual non-IBD control samples generally generated the
highest SDI figures and that these were significantly
higher (p < 0.05) than those from both the inflamed and
non-inflamed CD samples and from the non-inflamed
UC samples (Figure 3B).
Bacterial community structure comparisons
We next wanted to test whether or not the biopsy sam-
ples grouped together by disease cohort, by individual
or both. Cluster analysis using both the Jaccard coeffi-
cient and PCoA showed that the samples clustered
together according to donor (Figures 4 and 5) and that
there was no separation between the CD, UC and non-
IBD cohorts. There was also no separation based upon
the location of biopsy sampling. This suggests that,
despite differences in bacterial community composition
and diversity between IBD and non-IBD samples, inter-
individual variation is a stronger determinant of overall
gut bacterial composition than disease. Despite this,
although the paired samples clustered together, the
branch lengths in the dendrogram were longer than
might be expected if the community structure was
highly similar between paired biopsies, indicating that
there were still significant differences between the
inflamed and non-inflamed tissues.
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Figure 3 Measures of bacterial diversity in the mucosal
biopsies. 3A) Rarefaction analysis showing number of phylotypes
observed with increasing sequencing effort across all patient
cohorts. Data points show the observed diversity after each
individual biopsy sample was incorporated into the analysis. Colour-
coded errors bars show 95% confidence intervals for each patient
cohort. Note that, as each patient is incorporated into the analysis,
the gap between the number of phylotypes observed in non-IBD
patients compared to IBD patients grows larger. The reduction in
species richness appeared to be particularly significant in CD
patients. Number of sequences per sample: Non-IBD controls = 252-
489, CD Inflamed = 248-342, CD Non-inflamed = 287-445, UC
Inflamed = 267-469, UC Non-inflamed = 286-499. 3B) Mean
Shannon diversity indices (SDI) calculated from the individual
biopsies for each sample type. Significantly reduced SDI compared
to non-IBD control samples are indicated by * (p = < 0.05). Error
bars indicate standard deviation from the mean.
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Figure 2 Compositional analysis of 16S rRNA gene clone
libraries. Phylum-level classification of bacterial phylotypes in CD,
UC and non-IBD control patients showing significant reduction in
the proportion of Firmicutes sequences in UC samples relative to
non-IBD controls (*
a) and disruption in Firmicutes to Bacteroidetes
ratio in IBD patients relative to non-IBD controls (*
b).
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inflamed tissue
We therefore sought to properly determine whether or
not a characteristic localised dysbiosis between healthy
and inflamed tissue within individual IBD patients exists.
To test this we first performed whole community com-
parisons using ∫-LIBSHUFF [38], unweighted and
weighted UniFrac [39] and the parsimony P-test [40]
which all test whether or not two communities are sig-
nificantly different overall without indicating which phy-
lotypes cause the significance. We then used the Library
Compare tool at the RDPII website [41], which pin-
points significant differences between two communities
at all taxonomic designations from phylum to genus
level to try and discover which bacterial groups were
differentially abundant between the paired samples.
Analyses with these tools indicated that in 11 out of the
12 IBD patients robust statistically significant differences
between the inflamed and non-inflamed mucosal com-
munities existed (Table 2).
∫-LIBSHUFF analysis indicated a significant difference
in all of the UC patients and 4 out 6 CD patients.
Library Compare analysis confirmed that there were sta-
tistically significant differences between inflamed and
non-inflamed sites for most of these samples. However,
no obvious pattern was apparent and the statistically
significant differences were spread between a number of
phylogenetic groups (Table 2). Three of the sample
pairs that had significant comparisons with ∫-LIBSHUFF
( C D 3 ,U C 1a n dU C 5 )s h o w e dn os i g n i f i c a n td i f f e r e n c e s
with Library Compare. Interestingly, these discrepancies
may be explained by the UniFrac analysis. Unweighted
UniFrac does not take into account the relative abun-
dances of different phylotypes when comparing commu-
nities, only the species overlap. Weighted UniFrac also
takes into account the relative abundance of each spe-
cies. For the three sample pairs with no significant
Library Compare results the unweighted UniFrac com-
parison showed highly significant differences between
the paired communities, while the weighted comparison
did not (Table 2). This indicates that these paired sam-
ples had significantly different community membership
but that the overlapping members of the bacterial com-
munity that were present in both samples had similar
abundances, thus explaining the significant ∫-LIBSHUFF
results and the non-significant Library Compare results.
In contrast to this, the paired set of samples from CD
patient 4 were highly significantly different when
Figure 4 Cluster dendrogram generated using the Jaccard coefficient, illustrating relationship between bacterial species membership
and biopsy type across all samples included in the study. Crohn’s disease patients are indicated by numbers CD1-CD6. Ulcerative colitis
patients are indicated by UC1-UC6. Samples marked with “I” are from inflamed intestinal regions, those marked with “N” are from non-inflamed
regions. Non-IBD control samples are indicated with N1-N5. Adjacent bar charts show the Family level classification (as determined by the RDP
classifier) for each of the sequences per sample. Families coloured in yellow/brown belong to the Firmicutes phylum, blue = Bacteroidetes, pink =
Actinobacteria, green = Proteobacteria, black = all other sequences not belonging to the specified Families.
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icance when measured using the unweighted version.
Further analysis revealed that a Prevotella species was
3.6 times more abundant in the inflamed than non-
inflamed site and accounted for 25% of the total com-
munity in the inflamed sample, a difference that was
found to be significant to p < 0.00000001 with Library
Compare. As the two communities were not recognised
as significantly different with ∫-LIBSHUFF and
unweighted UniFrac it is possible that this was because,
regardless of the differential abundance, overall commu-
nity membership was similar across both samples. The
only sample pair to show no significant differences
between inflamed and non-inflamed tissue with either
∫-LIBSHUFF or Library Compare (patient CD6) was
characterised by a very low overall diversity, indicating
that the microbiota may have been particularly disturbed
in this patient.
As Library Compare is only able to classify sequences
down to the genus level we then sought to characterise
whether or not there were differences at the species
level. For this purpose we compared sequences that had
been grouped into phylotypes using DOTUR (99% iden-
tity) and assigned identities with MegaBLAST (see Addi-
tional file 1 ). While we were often able to observe
statistically significant differences between individual
phylotypes in single patients (data not shown) we were
Figure 5 Principal coordinates analysis of variation between
the bacterial communities present in all biopsy samples. Each
data point represents an individual sample. Blue circles denote non-
IBD control samples, red squares are Crohn’s disease samples, green
triangles are ulcerative colitis samples. Numbers indicate the donor
the samples were obtained from. The paired, inflamed and non-
inflamed, biopsy samples from each donor can be seen to cluster
together. Figure was calculated using unweighted Fast UniFrac [39].
Table 2 Comparison of bacterial composition from inflamed and non-inflamed tissue within individual IBD patients
using ∫-LIBSHUFF, unweighted and weighted UniFrac, the parsimony P-test and RDP Library Compare
Crohn’s Disease Patients Ulcerative Colitis Patients
CD1 CD2 CD3 CD4 CD5 CD6 UC1 UC2 UC3 UC4 UC5 UC6
∫-LIBSHUFF * ** ** n/s * n/s * * *** ** * **
UW UniFrac *** *** *** n/s *** *** *** *** ** *** *** ***
W UniFrac ** *** n/s *** * n/s n/s *** *** ** n/s *
P-Test *** *** *** *** *** *** *** *** *** *** *** ***
Library Compare
Firmicutes ↑** ↑*** ↓*** ↑***
>Clostridiales ↑*** ↓*** ↑***
>>Lachnospiraceae ↑*** ↓***
>>Ruminococcaceae ↓**
Bacteroidetes ↓** ↓*** ↑*** ↓***
>>>Bacteroides ↓***
>>>Parabacteroides ↓**
>>>Prevotella ↑*** ↑*** ↓***
Actinobacteria ↑**
>>>Collinsella ↑**
Proteobacteria ↓***
>>>Sutterella ↓***
Fusobacteria ↑*
>>>Fusobacterium ↑*
Key:- *** = P < 0.001, ** = P < 0.01, * = P < 0.05, n/s = P > 0.05. ↑ = Increased in inflamed vs. non-inflamed tissue, ↓ = Decreased in inflamed vs. non-inflamed
tissue. Bold = Phylum level classification, > = Order level classification, >> = Family level classification, >>> = Genus level classification.
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tify disease-specific phylotypes. Recently, a reduction in
Faecalibacterium prausnitzii has been implicated in CD
aetiology [31,42]. We did not observe a difference in
F. prausnitzii proportional abundance between healthy
and IBD patients but found that, when looking at paired
biopsies from individual IBD patients, this species was
almost always reduced in inflamed versus non-inflamed
tissue. This trend did not reach statistical significance
however. Species-level analysis also failed to identify any
pathogenic species that have been previously associated
with IBD such as Mycobacterium avium subspecies
paratuberculosis, Yersinia spp or Listeria spp. [43]. We
did recover E. coli/Shigella spp. from many CD samples
but as 16S rRNA gene sequence data does not provide
enough resolution to differentiate between commensal
and pathogenic strains we could not determine whether
or not these species were pathogenic. Sulphate-reducing
bacteria (SRB) have also been implicated in the patho-
genesis of IBD [44] but we recovered only one SRB
sequence, which had greater than 99% identity to Desul-
fovibrio piger, and this was detected in one of the non-
IBD control patients.
Discussion
To our knowledge, this is one of the largest clone library
studies investigating the microbiota in IBD. In contrast
to an earlier study by Frank et al., [30], which examined
a smaller number of clones from a large number of
patients, we sought instead to add to current knowledge
by obtaining a higher resolution of the IBD-associated
microbiota with particular emphasis placed on observing
differences between inflamed and non-inflamed colon
sites in the same patients. This was inevitably done in a
smaller number of patients and samples because of the
depth of molecular analysis required for each sample.
Our in-depth clone library analysis, utilizing the resol-
v i n gp o w e ro fn e a rf u l l - l e n g t h1 6 Sr R N Ag e n e
sequences, revealed significant differences in diversity
and composition between the mucosal microbiota of
healthy patients and IBD sufferers. The results also sug-
gest a tendency towards a reduction in Firmicutes and
an increase in Bacteroidetes species in IBD patients
compared to controls and also indicate that there is an
increase in Enterobacteriaceae in CD. Similar shifts in
composition, in either one or all of these groups, have
been reported by other investigators using both culture
[22] and a variety of molecular techniques [29,31,45-55].
A previous large-scale clone library analysis by Frank
et al., [30], however, reported a decrease in proportions
of Bacteroidetes and the Firmicutes family Lachnospira-
ceae in a subset of, but not all, IBD patients and an
increase in Proteobacteria. The observed discrepancies
between these two large-scale clone library studies may
in part be explained by different disease phenotypes,
dietary or other environmental differences, the effect of
inter-individual variation between patients or the differ-
ing number of samples studied and the depth of sequen-
cing between each study.
We also demonstrated a reduction in bacterial diver-
sity within IBD patients compared to controls and this
is in agreement with several previous studies
[24-27,56,57]. Our data shows, however, that despite the
differences between IBD and non-IBD patients in both
bacterial composition and diversity that samples clus-
tered predominantly by individual rather than disease.
Using both culture and molecular methods, many stu-
dies have demonstrated that the mucosal community
along the length of the colon is largely stable, in healthy
and IBD patients, and distinct from that recovered in
faeces [32-37]. Here we provide evidence instead for the
development of localised differences in mucosal micro-
biota structure in IBD. Our community comparison
results suggest that there may be differences between
inflamed and non-inflamed tissue, with significant
changes in the composition of the bacterial communities
at these sites. A number of prior studies have also
attempted to establish whether or not there is localised
dysbiosis in IBD between inflamed and non-inflamed
tissue. While two of these studies indicated that there is
a dysbiosis [58,59], the majority have suggested that this
is not the case [29,48,60-62]. Discrepancies between
these results and ours may result from the use of differ-
ing molecular methodology and/or the greater sequen-
cing depth we employed. DGGE/TGGE and FISH are
useful tools but the resolving power of these methods is
much lower than that for in-depth clone libraries cover-
ing the full length of the 16S rRNA gene [63]. In
addition, DGGE/TGGE cannot accurately describe
quantitative differences between dominant bands or
describe qualitative differences in sub-dominant species
and single bands on the gel may contain DNA from
more than one species [64].
While our results suggest that localised changes in the
mucosal microbiota do exist in IBD we were not able to
identify a bacterial species or cluster that was consis-
tently associated with the inflamed gut and therefore,
potentially, with IBD aetiology. Other large-scale clone
library analyses have also failed to identify specific
pathogens [29,30]. While their absence may indicate
that potential pathogens may simply form a very minor
component of the microbiota, these results do not sup-
port the hypothesis that a particular bacterial agent
causes IBD. Clone libraries generate inherent biases,
however, and it is possible that they are unable to
detect certain species due to methodological artefacts.
Indeed, this may be important with Mycobacterium
avium subspecies paratuberculosis, a member of the
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The absence of bifidobacteria from our dataset indicates
that our clone libraries also suffer from this same bias
against Actinobacteria. It is also worth noting that our
analysis would not detect any viral, archaeal or eukaryo-
tic aetiological agents. This may be important given
recent evidence suggesting a role for viruses in the
induction of at least some models of IBD [67].
Sequence-based microbiota comparisons such as ours
can of course only demonstrate associations and do not
provide information regarding mechanism or causation.
It is also difficult to differentiate between compositional
changes that may play a role in disease pathogenesis
and those which may simply have occurred as a result
of disease. However, given the absence of a specific and
recurring aetiological agent in the cumulative data
across all published IBD studies, which incorporate both
culture- and molecular-based methodologies, it is possi-
ble that the alterations in bacterial composition and
diversity seen between healthy and IBD patients and
between inflamed and non-inflamed mucosa may be, to
at least some extent, the result of the disturbed gut
environment rather than the direct cause of disease.
Indeed, there are a number of reasons why IBD is likely
to result in altered conditions for bacterial growth. For
example, the gut in IBD is likely to be a less stable
environment than that of healthy individuals, with more
exposure to antibiotics and other drug regimes, and
alterations in transit time. Microscopy studies have sug-
gested that there is a higher penetration of bacteria and
a greater bacterial load in the mucosal layer in IBD
patients [47,68] and the resulting inflammation drives
the localised release of antimicrobial compounds [69].
In addition, in UC there is a reduced mucus layer in
inflamed relative to non-inflamed regions [70].
Despite proportional increases in Enterobacteriaceae
and Bacteroidetes within IBD patients, if these organ-
isms were directly responsible for disease we might
expect them to be elevated at sites of inflammation and
this was not shown in our analysis. Taking into account
all of the above factors, the observed increases in these
bacterial groups in IBD patients as a whole may there-
fore simply reflect the adaptation of the individual
microbiota to the IBD gut environment. Bacteroides the-
taiotaomicron, for example, can adapt to inflammation
in an experimental mouse model by inducing genes that
metabolise host oxidative products [71] and inflamma-
tion per se has also been shown to promote the growth
of Enterobacteriaceae in mouse models [72,73]. Clearly,
further similar studies are required on a far greater
range of gut bacterial species so that we can better
understand the response of the gut microbiota to altera-
tions in environmental conditions.
Conclusions
This work demonstrates a dysbiosis, or imbalance, in
microbial community structure and composition in
inflammatory bowel disease patients relative to non-IBD
controls. It also indicates that inflamed tissue differs
from non-inflamed tissue, but not in a consistent or
predictable manner. Indeed, despite general trends such
as a reduction in diversity, the response to IBD may be
to some extent specific to the individual. This lends sup-
port to the emerging hypothesis that IBD is combinator-
ial in aetiology, with many different combinations of
genetic and environmental causes leading to similar
therapeutic responses [67], and highlights the impor-
tance of interconnection between the environment, the
microbiota and the host in health and disease.
Despite this, even if particular bacteria are not the
specific cause of IBD, altered immune responses may
act to select particular bacterial species through creation
of favourable microenvironments and might therefore
cause the outgrowth of potentially pathogenic commen-
sal species [74]. Shifts in the microbiota may therefore
still impact gut health by altering the antigenic exposure
to the gut mucosa or by reducing its exposure to benefi-
cial microbes and/or their metabolic products, thereby
initiating a cycle that favours recruitment and growth of
more pro-inflammatory species [17,75]. The observed
reduction in Firmicutes proportions, for example, might
lead to an undesirable affect on gut health. Recent work
describing the anti-inflammatory properties of one Fir-
micutes species, Faecalibacterium prausnitzii [42] illus-
trates this point.
Finally, results from metagenomic studies indicate
that, regardless of species composition, the collective
genomes of each individual’s microbiota appear to
encode a remarkably conserved set of functions [28]. If
similar, and potentially aggravating, factors are encoded
by multiple species, it is possible that we will be better
served in the future by looking at the complete gene
complement of the microbial community as a whole,
not just species composition. With this in mind, it is
hoped that further analysis of the complex interplay
between host and microbes will yield important insights
into the pathogenesis of IBD.
Methods
Patients
Patients were selected from those undergoing routine
colonoscopic assessment of IBD at Guy’sa n dS t .T h o -
mas’ Hospitals, London, UK. As controls, asymptomatic
individuals undergoing colonoscopy for a family history
of colorectal cancer or polyp surveillance were also
invited to take part. Written informed consent was
obtained from each patient and the study was granted
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Committee (Ref No. 06/Q0702/74). Patient information,
including sex, age and the location of the colon that
biopsies were taken from, is given in Table 1.
Colonoscopy was undertaken after prior preparation of
the colon with two sachets of sodium picosulphate. No
individuals received antibiotics in the preceding 2 months.
For those with CD or UC, mucosal biopsies were taken
from macroscopically inflamed and non-inflamed areas of
the colon using standard gape forceps. Once taken, biopsy
samples (approximately 1 × 2 mm) were placed in a cryo-
vial without preservative, immediately snap frozen in
liquid nitrogen, and stored at -70°C until analysis. Addi-
tional biopsy samples from the same area were also sent
for histological analysis. These biopsies were scored inde-
pendently for presence of ulceration, acute and chronic
inflammation by a single gastrointestinal pathologist. Prior
diagnosis of active CD or UC was determined by standard
clinical, radiological, endoscopic and histopathological cri-
teria. A modified Baron score with a range from 0-5,
where a score of 5 represents the most severe disease, was
used to grade the endoscopic severity of inflammation at
the site of each biopsy used in the study [76].
DNA extraction and sequence analysis
DNA was extracted from each mucosal biopsy sample
using the QIAamp
® DNA Mini-Kit (Qiagen, UK) and
the eluted DNA was stored at -20°C. 16S rRNA genes
were amplified using the broad-range bacterial primers
Bact-8F (5’-AGAGTTTGATCCTGGCTCAG-3’)a n d
Bact-1391R (5’-GACGGGCGGTGTGTRCA-3’) [34].
Clone library construction and sequencing were carried
out as described previously [72].
Sequences were aligned using the NAST aligner [77]
and these alignments were subject to extensive manual
curation using the ARB package [78] before further ana-
lysis. Sequences were tested for chimeras with Mallard
[79], Bellerophon at Greengenes [77] and Pintail [80]
and any that appeared to be chimeric were removed.
The sequences (deposited in GenBank under accession
numbers FJ503060-FJ513069) were initially given a
broad classification to the phylum and family levels
using the Classifier tool at the RDPII website [41]. To
obtain more detailed taxonomic information the
sequences were then divided into phylotypes. Distance
matrices were generated in ARB with the Olsen correc-
tion and a 60% maximal-base frequency filter applied.
This filter removed many ambiguously-aligned columns
but was not so stringent that distinct species were com-
monly merged into single phylotypes. Distance matrices
were then entered into the DOTUR program [81] set to
the furthest neighbour and 99%-similarity setting. The
resulting phylotypes were then assigned similarities to
nearest neighbours using MegaBLAST [82].
To determine the depth of coverage in each of the
clone libraries Good’s coverage was calculated using the
mothur software package [40]. Using this estimator the
median coverage across all samples was found to be
94.35% (range of 83.73-97.3%).
Shannon diversity indices were calculated for each
library by entering distance matrices generated in ARB,
with the Olsen correction and a 60% maximal base-
frequency filter applied, into DOTUR [81]. Rarefaction
curves for each sample were calculated using mothur [40].
Community structure comparisons across the whole
dataset, incorporating unweighted and weighted Uni-
Frac, Parsimony testing and cluster analysis using the
Jaccard coefficient, were performed using mothur and
w e r eb a s e do na na l i g n m e n tc r e a t e di nm o t h u ru s i n g
the reference SILVA-alignment and with the 60% maxi-
mal-base filter and Olsen correction applied prior to dis-
tance matrix construction in ARB. Cluster dendrograms,
with added bar charts showing the microbial composi-
tion of each sample, were visualised using the iTOL web
package [83].
Paired (inflamed and non-inflamed) biopsy sample
sequences from individual patients were aligned using
the NAST aligner and were again extensively corrected
in the ARB package [78] before further analysis. Olsen-
corrected, 60% maximal-base frequency filtered dis-
tance matrices were subjected to ∫-LIBSHUFF analysis
[38]. Unaligned paired-sample sequences were used as
input for the Library Compare tool at the RDPII web-
site [41].
Principal coordinates analysis (PCoA) plots were gen-
erated using the Fast UniFrac web application [39]
based upon neighbour joining trees created in ARB,
with 60% maximal-base frequency filter and Olsen cor-
rection applied, using the sequences aligned to the
SILVA reference in mothur as initial input.
Quantitative PCR (qPCR)
Total bacteria were quantified in 25 of the 29 biopsies
by qPCR (CD1 non-inflamed, CD5 inflamed, CD5 non-
inflamed and UC4 non-inflamed were not included in
the analysis due to a lack of DNA from these samples).
All PCRs were performed using a Stratagene Mx3000P
thermal cycler, in conjunction with Stratagene MxPro
qPCR Software. Each reaction contained a total volume
of 20 μl per well and was performed in triplicate. qPCR
reactions contained 10 ng of forward and reverse pri-
mer, 10 μl Brilliant II SYBR Green qPCR Master Mix
(Agilent Technologies, La Jolla, CA), ~ 900 pg of tem-
plate DNA (1:100 dilutions of sample genomic DNA
preparations) and were made up to 20 μlw i t hR N a s e
free water. A 466-bp fragment of the bacterial 16S
rRNA gene was amplified using the forward primer
5’-TCCTACGGGAGGCAGCAGT-3’ and the reverse
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[84]. The thermal cycling conditions were 50°C for
2 minutes and 95°C for 5 minutes followed by 40 cycles
of denaturing at 95°C for 15 seconds, primer annealing
at 60°C for 30 seconds and DNA extension at 72°C for
90 seconds. Finally a dissociation step was added to qua-
litatively assess reaction product specificity (temperature
raised to 95°C, cooled to 60°C then slowly heated back
to 95°C) for melt curve analysis of the PCR products.
Extracted DNA from a pure Bacteroides vulgatus
(ATCC 8482) culture was prepared into a series of ten-
fold dilutions in RNase free water ranging from 1 × 10
6
copies to one copy and used as a positive control in
order to make a standard curve. Quantification of tem-
plate concentrations was made by linear extrapolation of
baseline-subtracted data from the bacterial dilution ser-
ies standard curve. For each reaction a threshold of
luminescence was determined and compared to the
standard curve. Thus for each sample an equivalent con-
centration given in colony forming units could be
established.
Statistical analysis
For the qPCR and compositional results the Mann-
Whitney U test was used for comparisons between two
groups and the Kruskall-Wallace method, analogous to
one-way analysis of variance, to compare more than two
groups. The levels of significance reported were not
adjusted to take account of multiple comparisons. As
these were multiple comparisons, p values <1% were
considered significant to imply strong evidence of a
difference.
Additional material
Additional File 1: Species-level analysis of mucosa-associated
microbiota at inflamed and non-inflamed sites within individual
patients and within non-IBD controls. Phylotypes generated using
DOTUR (99% identity) were assigned identities with MegaBLAST.
Phylotypes were given the name of the closest-matching environmental
clone in the NCBI database and also the closest cultured relative. If
closest matching identities were >99% these were not indicated in the
figure, identities <99% are shown in brackets. The bacterial phyla
individual phylotypes were mapped to are indicated by the coloured
boxes.
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